[go: up one dir, main page]

MX2021003143A - Composicion de anticuerpo anti-tfpi altamente eficaz. - Google Patents

Composicion de anticuerpo anti-tfpi altamente eficaz.

Info

Publication number
MX2021003143A
MX2021003143A MX2021003143A MX2021003143A MX2021003143A MX 2021003143 A MX2021003143 A MX 2021003143A MX 2021003143 A MX2021003143 A MX 2021003143A MX 2021003143 A MX2021003143 A MX 2021003143A MX 2021003143 A MX2021003143 A MX 2021003143A
Authority
MX
Mexico
Prior art keywords
tfpi antibody
highly efficient
antibody composition
efficient anti
tfpi
Prior art date
Application number
MX2021003143A
Other languages
English (en)
Inventor
Min Jung Kim
Geun Hye Yeo
Haeng Eun Song
Ji Yoon Park
Yuna Kim
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2021003143A publication Critical patent/MX2021003143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a una composición farmacéutica de anticuerpo anti-TFPI altamente eficaz que incluye un anticuerpo anti-TFPI para el tratamiento de la hemofilia, en donde el contenido de HCP en una sustancia farmacológica es inferior a 10.0 ng/mg, y el contenido de LPA en la sustancia de fármaco o el medicamento es inferior a 1.0 ng/mg. De conformidad con la presente descripción, se puede proveer una composición de anticuerpo anti-TFPI altamente eficaz que tenga contenidos muy bajos de HCP y LPA proveyendo un proceso de separación/purificació n capaz de reducir al mínimo la generación de polímero de anticuerpo anti-TFPI, y se puede usar de manera eficaz para el tratamiento de pacientes con hemofilia inducida por anticuerpos y para la prevención de la enfermedad de la coagulación sanguínea.
MX2021003143A 2018-09-21 2019-09-06 Composicion de anticuerpo anti-tfpi altamente eficaz. MX2021003143A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180113974A KR102337683B1 (ko) 2018-09-21 2018-09-21 고효율 항-tfpi 항체 조성물
PCT/KR2019/011582 WO2020060087A1 (en) 2018-09-21 2019-09-06 Highly efficient anti-tfpi antibody composition

Publications (1)

Publication Number Publication Date
MX2021003143A true MX2021003143A (es) 2021-05-14

Family

ID=69887465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003143A MX2021003143A (es) 2018-09-21 2019-09-06 Composicion de anticuerpo anti-tfpi altamente eficaz.

Country Status (14)

Country Link
US (1) US12247082B2 (es)
EP (1) EP3853259A4 (es)
JP (2) JP7419355B2 (es)
KR (1) KR102337683B1 (es)
CN (1) CN112771081A (es)
AR (1) AR116426A1 (es)
AU (1) AU2019342637B2 (es)
BR (1) BR112021005273A2 (es)
CA (1) CA3111179A1 (es)
EA (1) EA202190825A1 (es)
MX (1) MX2021003143A (es)
MY (1) MY198049A (es)
TW (1) TWI738054B (es)
WO (1) WO2020060087A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
EP2738178A1 (en) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
CN102257006A (zh) * 2008-10-20 2011-11-23 雅培制药有限公司 使用a蛋白亲和层析分离和纯化抗体
KR101600308B1 (ko) 2008-12-22 2016-03-07 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
US8546548B2 (en) * 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
SI3345615T1 (sl) * 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)
ES2983470T3 (es) * 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
MX354845B (es) 2010-05-18 2018-03-22 Abbvie Inc Star Aparato y proceso de purificación de proteínas.
CN105055306B (zh) * 2010-05-28 2019-10-01 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
KR101941742B1 (ko) * 2012-06-21 2019-01-23 신톤 바이오파머슈티칼즈 비.브이. 항체의 정제 방법
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TW201522368A (zh) * 2013-03-15 2015-06-16 Bayer Healthcare Llc 抗組織因子路徑抑制劑之前藥抗體
RU2662668C2 (ru) 2013-05-06 2018-07-26 Санофи Способ непрерывной многостадийной очистки антител
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
WO2015070069A1 (en) * 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of dvd-igs
MX2016008498A (es) * 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN107428838B (zh) * 2015-02-25 2021-01-01 财团法人牧岩生命科学研究所 结合tfpi的新型抗体以及包含所述抗体的组合物
KR101744899B1 (ko) * 2015-02-25 2017-06-08 재단법인 목암생명과학연구소 신규 항-tfpi 항체 및 이를 포함하는 조성물
KR101804988B1 (ko) 2015-09-24 2017-12-07 재단법인 목암생명과학연구소 신규 항-tfpi 항체 및 이를 포함하는 조성물
JP6664467B2 (ja) * 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
EP3397973A4 (en) 2015-12-30 2019-06-05 Bio-Rad Laboratories, Inc. DROP ANALYSIS SYSTEM WITH AUTOMATIC CALIBRATION
PL3472314T3 (pl) * 2016-06-17 2021-11-22 Alexion Pharmaceuticals, Inc. Przygotowanie pochodnych czynnika xa

Also Published As

Publication number Publication date
JP7419355B2 (ja) 2024-01-22
AU2019342637A1 (en) 2021-05-13
EP3853259A4 (en) 2022-06-15
AR116426A1 (es) 2021-05-05
TW202017596A (zh) 2020-05-16
JP2022501379A (ja) 2022-01-06
MY198049A (en) 2023-07-28
US20220025067A1 (en) 2022-01-27
CA3111179A1 (en) 2020-03-26
EA202190825A1 (ru) 2021-06-17
CN112771081A (zh) 2021-05-07
JP2024020287A (ja) 2024-02-14
TWI738054B (zh) 2021-09-01
AU2019342637B2 (en) 2024-04-18
BR112021005273A2 (pt) 2021-06-15
KR20200034321A (ko) 2020-03-31
KR102337683B1 (ko) 2021-12-13
US12247082B2 (en) 2025-03-11
EP3853259A1 (en) 2021-07-28
WO2020060087A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
MX2022000709A (es) Regimenes de tratamiento con dexmedetomidina no sedante.
GB0410266D0 (en) Treatment of apoptosis
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
JP2014139220A5 (es)
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
ATE318133T1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
EP4233913A3 (en) Improved bromocriptine formulations
GB2456976A (en) System and process for producing a low suspended solids solution and uses therefore
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
MX2021003143A (es) Composicion de anticuerpo anti-tfpi altamente eficaz.
EA024810B1 (ru) Применение сополимера натрийкарбоксиметилцеллюлозы и госсипола в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями, содержащая его фармацевтическая композиция и способ лечения
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
MX2022015232A (es) Composicion farmaceutica acuosa de levilimab y su uso.
CN105078944A (zh) Isopaucifloral F在制备抗骨质疏松药物中的用途
MX2022012001A (es) Tratamiento preventivo de la migra?a.
WO2020061067A3 (en) Compositions and methods for treating bone injury
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma
EP4491231A3 (en) Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
Kang et al. Recurrent pulmonary embolism during dabigatran treatment in a patient with immune thrombocytopenic purpura
Ackery et al. Tranexamic acid for trauma-related hemorrhage
EP3535401A4 (en) MICRO-ORGANISM FOR DELIVERY OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A GASTROINTESTINAL DISEASE, WHICH EXPRESSES AND SECRETS A CYSTATIN, AND PHARMACEUTICAL COMPOSITION CONSISTING OF THIS MICRO-ORGANISM FOR THE PREVENTION OR TREATMENT OF A GASTROINTESTINAL DISEASE